Track topics on Twitter Track topics that are important to you
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases. Xofigo shown in a pivotal phase III trial to significantly improve overall survival. Xofigo® with...
On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...
PolyXen® is an enabling technology for protein drug delivery. It uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides...
ImuXen® is a liposomal technology platform designed to improve the delivery and effectiveness of DNA, protein and polysaccharide vaccines. Proof of concept preclinical studies with a number of...
Medical castration is associated with a higher risk of adverse effects than surgical castration in men with metastatic prostate cancer, research published in JAMA Oncology has found.1Androgen...
(The JAMA Network Journals) Surgical castration to remove the testicles (orchiectomy) of men with metastatic prostate cancer was associated with lower risks for adverse effects compared with men who u...
LONDON - Researchers from Sweden are seeking crowdfunding to test a type of "chemical castration" in men who report having paedophilic thoughts and fantasies.
A new study published in Nature Communications is suggesting that castration-resistant prostate cancer has particular metabolic characteristics that may open new possibilities for treatment.
LONDON, April 7 (Reuters) - Researchers from Sweden are seeking crowdfunding to test a type of "chemical castration" in men who report having paedophilic thoughts and fantasies.
(New York Times) – The Indonesian president, Joko Widodo, signed a decree on Wednesday authorizing chemical castration for convicted child sex offenders and requiring those released on parole to...
Surgical castration has a lower risk for fractures, peripheral arterial disease, thromboembolism, and cardiac complications than GnRH agonists in metastatic prostate cancer. Medscape Medical News
Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of
The aim of the study was to describe the process of designing and producing a video to promote HIV testing in Peruvian men who have sex with men (MSM). The process involved the following steps: identi...
Recent therapeutic strategies for castration-resistant prostate cancer have focused on immunomodulation, especially the PD-1/PD-L1 pathway related to tumor-infiltrating lymphocytes. Few cases of castr...
This paper aims at developing an automated gastroscopic video summarization algorithm to assist clinicians to more effectively go through the abnormal contents of the video.
Androgen-deprivation therapy (ADT) through surgical castration is equally effective as medical castration in controlling prostate cancer (PCa). However, the adverse effect profiles of both ADT groups ...
A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane.